Aurelius Health Group review

Aurelius publishes its GLP-1 subscription price and acknowledges limited large-scale microdose trial data. It also makes strong comparative side-effect and muscle-preservation claims without established large-scale comparative trial support. NAD⁺ is a protocol add-on, not the product covered by a separate published NAD⁺ price. Read the renewal cutoff and conditional refunds before enrolling.

Aurelius Health Group is a telehealth practice, operated by Aurelius Health, Inc., built around compounded tirzepatide microdose injections, a low-dose dual GIP/GLP-1 approach rather than standard full-dose therapy. Its protocols are organized as outcome stacks (performance and cognition, metabolic health, sleep and recovery), with NAD⁺, L-carnitine, B12 or inositol stacked in. It is the microdose protocol, not the NAD⁺, that is the product; the NAD⁺ is an accessory to it. There is no capsule option.

The homepage advertises physician review, monthly check-ins and messaging. Terms distinguish the platform from independent medical groups, giving OpenLoop Healthcare Partners as an example. They list RedRock, Health Warehouse, Precision Compounding Pharmacy and Triad Rx as pharmacy partners. These disclosures do not establish your assigned clinician or pharmacy or independently verify credentials. State availability and the exact add-on formulation need confirmation.

The microdose GLP-1 subscription is $89 for the first month and $199/month thereafter; no separate NAD⁺ add-on price is published. Cancellation requires notice at least 72 hours before the next bill. The first-72-hour refund requires that no subscription services have been received; medical disqualification also qualifies for a refund. Monthly charges are not refunded for the cancellation month or earlier months. For multi-month payments, the policy permits refunds for months with no medication shipped. Confirm the full NAD⁺-inclusive debit before comparing.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The tirzepatide is described as compounded, and is not brand-name Mounjaro or Zepbound, nor therapeutically equivalent to either. Two evidence points need separating. Microdosing: sub-therapeutic dosing has a thinner trial base than full-dose therapy and should be expected to produce smaller results, with limited evidence for comparative weight-loss, side-effect or muscle-preservation outcomes. The NAD⁺ add-on: injectable NAD⁺ has no controlled human outcome trials supporting the energy or longevity claims the category is sold on, and the single human intravenous study was a pharmacokinetic pilot showing infused NAD⁺ clears from plasma quickly. The NAD⁺ evidence that exists is with the oral precursors NR and NMN, which reliably raise blood NAD⁺: a biomarker, not an outcome. Stacking an unproven add-on onto a deliberately reduced dose is worth thinking about carefully rather than treating as a bonus. Individual results vary.